Macquarie Group
LFCR icon

Macquarie Group’s Lifecore Biomedical LFCR Stock Holding History

Macquarie Group’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,191
Closed -$8.77K – 1212
2025
Q3 		$8.77K Buy
+1,191
New +$9.01K ﹤0.01% 1573
2025
Q2 		– Sell
-904
Closed -$6.36K – 1716
2025
Q1 		$6.36K Buy
+904
New +$5.62K ﹤0.01% 1669
2024
Q2 		– Sell
-713
Closed -$4 – 2024
2024
Q1 		$4 Buy
+713
New +$5.1K ﹤0.01% 1810
2016
Q1 		– Sell
-162,553
Closed -$1.92M – 1563
2015
Q4 		$1.92M Sell
162,553
-155,204
-49% -$1.91M ﹤0.01% 944
2015
Q3 		$3.71M Hold
317,757
– – 0.01% 806
2015
Q2 		$4.58M Sell
317,757
-1,000
-0.3% -$14.4K 0.01% 764
2015
Q1 		$4.45M Buy
318,757
+48,523
+18% +$670K 0.01% 782
2014
Q4 		$3.73M Hold
270,234
– – 0.01% 806
2014
Q3 		$3.31M Buy
270,234
+37,500
+16% +$468K 0.01% 836
2014
Q2 		$2.91M Hold
232,734
– – 0.01% 908
2014
Q1 		$2.6M Buy
232,734
+13,000
+6% +$143K ﹤0.01% 924
2013
Q4 		$2.66M Sell
219,734
-5,000
-2% -$59.7K ﹤0.01% 876
2013
Q3 		$2.74M Sell
224,734
-12,419
-5% -$173K 0.01% 800
2013
Q2 		$3.13M Buy
+237,153
New +$3.28M 0.01% 719

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GC
Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return

Macquarie Group's LFCR Position: Q4 2025 in Review

Macquarie Group sold out of Lifecore Biomedical (LFCR) in Q4 2025, closing a stake of 1,191 shares — an estimated $8.77K sold.

Macquarie Group first reported a position in LFCR in Q2 2013 and held it in 14 quarters. The position peaked at $4.58M in Q2 2015. 103 funds tracked by Wall St. Rank hold LFCR as of Q4 2025.

  • Macquarie Group reported no remaining Lifecore Biomedical position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 1,191 Lifecore Biomedical shares in Q4 2025, an estimated $8.77K.
  • Macquarie Group first reported a position in Lifecore Biomedical in Q2 2013 and held it in 14 quarters.
  • Macquarie Group's Lifecore Biomedical position peaked at $4.58M in Q2 2015.
  • 103 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.